AstraZeneca PLC (ETR:ZEG)
Germany
· Delayed Price · Currency is EUR 122.30
+1.25 (1.03%)
Apr 24, 2025, 5:35 PM CET
AstraZeneca Revenue
In the year 2024, AstraZeneca had annual revenue of $54.07B USD with 18.03% growth. AstraZeneca had revenue of $14.89B in the quarter ending December 31, 2024, with 23.84% growth.
Revenue
$54.07B
Revenue Growth
+18.03%
P/S Ratio
3.59
Revenue / Employee
$573.41K
Employees
94,300
Market Cap
187.74B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck KGaA | 21.16B |
| Siemens Healthineers AG | 22.67B |
| Fresenius SE & Co. KGaA | 21.83B |
| Bayer Aktiengesellschaft | 46.61B |
| Sartorius Aktiengesellschaft | 3.44B |
| Fresenius Medical Care AG | 19.34B |
| Carl Zeiss Meditec AG | 2.08B |
| Fielmann Group AG | 2.16B |
AstraZeneca News
- 1 day ago - Tempus AI Stock Is Ripping Higher Wednesday: What's Fueling The Move? - Benzinga
- 1 day ago - Drug firm bosses call for price increases in Europe amid tariff uncertainty - Evening Standard
- 1 day ago - Tempus expands partnership with AstraZeneca to build oncology model - Seeking Alpha
- 1 day ago - Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology - Wallstreet:Online
- 1 day ago - Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology - Business Wire
- 1 day ago - AstraZeneca CEO says Europe must protect its health sovereignty, is falling behind on pharma investments - Reuters
- 1 day ago - AstraZeneca rejoins leading U.S. drug lobby group after two-year absence - Reuters
- 3 days ago - AstraZeneca's Enhertu, pertuzumab combo improves breast cancer treatment in trial - Seeking Alpha